

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3022820

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	IMMUNOCOPEA LIMITED	12/31/2013
RECEIVING PARTY DATA		
Name:	INFIRST HEALTHCARE LIMITED	
Street Address:	100 FETTER LANE	
City:	LONDON	
State/Country:	UNITED KINGDOM	
Postal Code:	EC4A 1BN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	13365828
CORRESPONDENCE DATA		
Fax Number:	(805)322-4469	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949-954-7988	
Email:	tamara_rodriguez@one3ip.com	
Correspondent Name:	ONE3 IP MANAGEMENT, P.C.	
Address Line 1:	5405 ALTON PARKWAY, SUITE 5A, 764	
Address Line 4:	IRVINE, CALIFORNIA 92604	
ATTORNEY DOCKET NUMBER:	3IPSK1.0003US	
NAME OF SUBMITTER:	DEAN G. STATHAKIS	
SIGNATURE:	/Dean G. Stathakis/	
DATE SIGNED:	09/15/2014	
Total Attachments: 8		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page1.tif		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page2.tif		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page3.tif		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page4.tif		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page5.tif		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page6.tif		
source=Patent Assignment Immunocopea Ltd to infirst healthcare-signed- 31 Dec 2013-REDACTED#page7.tif		

PATENT

Dated 31st December 2013

(1) IMMUNOCOPEA LIMITED

- and -

(2) INFIRST HEALTHCARE LIMITED

INTELLECTUAL PROPERTY ASSIGNMENT AND TRANSFER AGREEMENT

DAC Beachcroft LLP
100 Fetter Lane London EC4A 3BN UK
tel: +44 (0) 20 7242 1011 fax: +44 (0) 20 7831 6630
DX 45 London

113311805_1.DOC

PATENT
REEL: 033741 FRAME: 0373

THIS ASSIGNMENT (this "Assignment") is dated _____ 31st _____ December 2013.

Parties

- (1) **IMMUNOCOPEA LIMITED** incorporated and registered in the Republic of Ireland with company number 489367 whose registered office is at 70 Sir John Rogerson's Quay, Dublin 2, The Republic of Ireland (the "Assignor"); and
- (2) **INFIRST HEALTHCARE LIMITED** a company incorporated under the laws of England and Wales with company number: 08077285 and whose registered office is at 100 Fetter Lane, London, EC4A 1BN, UK (the "Assignee").

1. INTERPRETATION

1.1 In this Assignment, the following words have the following meanings:

"Improvements"	any improvement, enhancement or modification to any products falling within the scope of any of the claims of the Patents and which relates to the use of ibuprofen to treat pain and inflammatory diseases;
"Patents"	all intellectual property rights under the patents and/or applications described in the Schedule hereto together with all continuations, continuations in part and divisionals of such applications and all re-issues, re-examinations and extensions of such patent(s).

2. ASSIGNMENT

2.1 For good and valuable consideration [REDACTED] the Assignor hereby ASSIGNS to the Assignee, full title to:

- 2.1.1 the Patents;
- 2.1.2 the Improvements; and
- 2.1.3 all of Assignor's right, title and interest in and to all intellectual property rights and know-how which it holds now or in the future including without limitation such rights relating to the use of ibuprofen to treat pain and inflammatory disease;

and the Assignor hereby TRANSFERS to the Assignee all of its other assets in relation to the use of ibuprofen in the treatment of pain and inflammatory disease (except for plant and machinery and employment agreements) including without limitation, confidential information (e.g. data and manufacturing formulae), the benefit of relevant agreements with third parties and regulatory applications and submissions which have been made in the Assignor's name (whether complete or incomplete).

3. THIRD PARTY LIABILITIES

The Assignee shall (as primary obligor) pay, settle and/or discharge any payments, costs, expenses, obligations and liabilities of any description due from time to time after the date hereof (referred to collectively as the "**Liabilities**") to third parties in respect of the Patents, Improvements and intellectual property rights assigned, and other assets transferred, under clause 2.1 above provided that the Assignor delivers valid documentary evidence of the Liability (e.g. in the form of an invoice), and to the extent that such Liabilities are not paid, settled and/or discharged by the Assignee, the Assignee shall indemnify and keep indemnified the Assignor and hold the Assignor harmless from and against all losses (whether direct or indirect) damages, costs, actions, awards, penalties, fines, proceedings, claims, demands and liabilities (including without limitation, reasonable legal and other professional fees and expenses) which the Assignor may suffer, sustain, incur, pay or be put to by reason or on account of or arising from the Assignee's failure to pay, settle or otherwise discharge the Liabilities.

4. GOVERNING LAW AND JURISDICTION

- 4.1 This Assignment and any disputes or claims arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) are governed by and construed in accordance with the laws of England.
- 4.2 The parties irrevocably agree that the courts of England have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).

5. MISCELLANEOUS

- 5.1 This Assignment may be executed in one or more counterparts, each of which, shall be deemed to be an original but all of which together shall constitute one and the same instrument.

This document has been signed on behalf of the parties hereto and is delivered and takes effect on the date stated at the beginning of it.

SCHEDULE

Patents

Reference #	Title	CNTRY	Serial #	Filed Date	Patent #	Issue Date	Status	Category	Expiration
1958652.00002GB	METHOD OF PREPARING OILY IBUPROFEN FORMULATION	GB	1101827.9	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00002.1GB	SOLID DOSE FORM	GB	1113730.4	10/08/2011			PENDING	BC1054	06/05/2021
1958652.00002US	COMPOSITIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES	US	13365.824	03/02/2012			PUBLISHED	BC1054	03/02/2032
1958652.00002WO	METHOD OF PREPARING A COMPOSITION	WO	PCT/GB2012/050242	03/02/2012			PUBLISHED	SC1054	04/02/2014
1958652.00003GB	HYPERLIPIDEMIA	GB	1113729.6	10/06/2011			PENDING	BC1054	10/06/2031
1958652.00003WO	COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES	WO	PCT/GB2012/050241	03/02/2012			PUBLISHED	BC1054	
1958652.00011AU	TREATMENT OF MICROBIAL INFECTIONS	AU	2010317727	05/11/2010			PENDING	BC1054	05/11/2030
1958652.00011BR	TREATMENT OF MICROBIAL INFECTIONS	BR	BR1120120112519	05/11/2010			PENDING	BC1054	05/11/2030
1958652.00011CA	TREATMENT OF MICROBIAL INFECTIONS	CA	2,780,614	05/11/2010			PENDING	BC1054	05/11/2030
1958652.00011CN	TREATMENT OF MICROBIAL INFECTIONS	CN	201020061247.4	05/11/2010			PUBLISHED	BC1054	05/11/2030

11301805_1.DOC

Page 3

1958652.00011EG	TREATMENT OF MICROBIAL INFECTIONS	EG	8502012PCT	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011EP	TREATMENT OF MICROBIAL INFECTIONS	EP	10773965.8	09/11/2010			PUBLISHED	BC1054	09/11/2030
1958652.00011GB	TREATMENT OF MICROBIAL INFECTIONS	GB	1001837.2	04/02/2010			PUBLISHED	BC1054	04/02/2030
1958652.00011IL	TREATMENT OF MICROBIAL INFECTIONS	IL	219771	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011IN	TREATMENT OF MICROBIAL INFECTIONS	IN	5114DELNP/2012	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011JP	TREATMENT OF MICROBIAL INFECTIONS	JP	2012-538408	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011MX	TREATMENT OF MICROBIAL INFECTIONS	MX	MX/a/2012/005551	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011NZ	TREATMENT OF MICROBIAL INFECTIONS	NZ	538946	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011RU	TREATMENT OF MICROBIAL INFECTIONS	RU	2012124039	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011SG	TREATMENT OF MICROBIAL INFECTIONS	SG	201203454-2	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011TH	TREATMENT OF MICROBIAL INFECTIONS	TH	1201002197	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011UA	TREATMENT OF MICROBIAL INFECTIONS	UA	201208988	09/11/2010			PENDING	BC1054	09/11/2030
1958652.00011US	TREATMENT OF MICROBIAL INFECTIONS	US	13569.534	11/05/2012			PENDING	BC1054	
1958652.00011WO	TREATMENT OF MICROBIAL INFECTIONS	WO	PCT/GB2010/051858	09/11/2010			NAT PHASE	BC1054	11/11/2012
1958652.00011ZA	TREATMENT OF MICROBIAL INFECTIONS	ZA	2012/4249	09/11/2010			PENDING	BC1054	09/11/2030


1958652.00012AU	TREATMENT OF RESPIRATORY DISORDERS	AU	201112256	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012BR	TREATMENT OF RESPIRATORY DISORDERS	BR	BR1120120194674	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012CA	TREATMENT OF RESPIRATORY DISORDERS	CA	2788786	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012CN	TREATMENT OF RESPIRATORY DISORDERS	CN	201180018052.9	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012EP	TREATMENT OF RESPIRATORY DISORDERS	EP	11702694.8	04/02/2011			PUBLISHED	BC1054	04/02/2031
1958652.00012IN	TREATMENT OF RESPIRATORY DISORDERS	IN	7715/DELNP/2012	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012JP	TREATMENT OF RESPIRATORY DISORDERS	JP	2012.551685	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012MX	TREATMENT OF RESPIRATORY DISORDERS	MX	MX/a/2012/RR9052	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012NZ	TREATMENT OF RESPIRATORY DISORDERS	NZ	601594	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012RU	TREATMENT OF RESPIRATORY DISORDERS	RU	2012137785	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012SG	TREATMENT OF RESPIRATORY DISORDERS	SG	201305786-5	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00012US	TREATMENT OF RESPIRATORY DISORDERS	US	13/576,758	02/08/2012			PENDING	BC1054	04/02/2031
1958652.00012WO	TREATMENT OF RESPIRATORY DISORDERS	WO	PCT/GB2011/050189	04/02/2011			NAT PHASE	BC1054	05/02/2013
1958652.00012ZA	TREATMENT OF RESPIRATORY DISORDERS	ZA	2012/5629	04/02/2011			PENDING	BC1054	04/02/2031

1253852 00014GB	TREATMENT OF RESPIRATORY DISORDERS	GB	1018289.7	29/10/2010	PENDING	BC1054	29/10/2030
1253852 00014 1GB	INFLAMMATORY DISEASE	GB	1113728.8	10/08/2011	PUBLISHED	BC1054	06/05/2021
1253852 00014WO	INFLAMMATORY DISEASE	WO	PCT/SE2011052115	31/10/2011	PUBLISHED	BC1054	29/10/2013


SIGNED on behalf of IMMUNOCOPEA LIMITED)
a company incorporated under the laws)
of the Republic of Ireland by Manfred Scheske,)
being a person who, in accordance with the)
laws of that jurisdiction, is acting under the)
authority of the company in the presence of:)


Director

WITNESS:

Signature: 
Name: MARY O'HAGAN
Address: 45 BEECH STREET,
LONDON EC2Y 8AA
Occupation: OFFICE MANAGER
(PLEASE COMPLETE IN CAPITALS)

SIGNED on behalf of INFIRST HEALTHCARE)
LIMITED a company incorporated under the laws of)
England and Wales, acting by Andrew Waters)


Director